Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ISA 2022 | Rationale for anti-amyloid therapy in systemic amyloidosis

Marina Ramirez-Alvarado • 7 Sep 2022
ISA 2022
Amyloidosis Rare Diseases

Marina Ramirez-Alvarado, PhD, Mayo Clinic, Rochester, MN, outlines the kinetic and thermodynamic rationale for anti-amyloid therapy in systemic amyloidosis. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

Disclosures

Honorarium from Attralus

More from Marina Ramirez-Alvarado

The importance of early diagnosis in systemic amyloidosis 1:25
The importance of early diagnosis in systemic amyloidosis
Marina Ramirez-Alvarado • 7 Sep 2022
Closing the gap between basic and clinical research in AL and ATTR amyloidosis 1:15
Closing the gap between basic and clinical research in AL and ATTR amyloidosis
Marina Ramirez-Alvarado • 7 Sep 2022

Related Videos

Using artificial intelligence to accelerate patient eligibility screening in clinical trials 1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
Molecular classification of Waldenström’s macroglobulinemia: the identification of two subtypes 2:03
Molecular classification of Waldenström’s macroglobulinemia: the identification of two subtypes
Gareth Morgan • 7 Dec 2025
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals